Regarding HCC, a catenin beta 1 (CTNNB1)-activating mutation is frequently observed and reported to flourish in an immune-desert tumor microenvironment, partly via C-C motif chemokine ligand 5 (CCL5) downregulation [8]. This evidence concerns the gene CCL5 and hepatocellular carcinoma.